Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BYFrontiers in endocrinology

Prostate cancer: advancements in targeted therapies

  • Ilesha Ewart1
  • Manreet Randhawa1
  1. 1Beatson West of Scotland Cancer Centre , ,
Read full textPDFDOICite

Abstract

Prostate cancer is the most common cancer diagnosed in men. Metastatic castration-resistant prostate cancer (mCRPC) is associated with significant morbidity and mortality. The last decades have seen the introduction of multiple new therapeutic agents, such as androgen receptor pathway inhibitors, PARP inhibitors, new cytotoxic agents, and radioligand therapies. Further advancements are being made with immunotherapy utilising new molecular targets. As these treatments move earlier in the treatment pathway, determining the optimal treatment sequencing becomes the challenge. This review aimed to highlight established treatments, recent developments, and promising therapies in mCRPC.

Related

  1. Advancements and future directions in transformative therapies of prostate cancer
    Jinge Zhao, Bo Tang, Hao Zeng +1
    Chinese Medical JournalPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  2. Oral Targeted Therapies and Clinician Comanagement Among Men With Advanced Prostate Cancer
    Arnav Srivastava, Anqi Sun, Megan E. V. Caram +2
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref
  3. Hippo pathway in cancer ferroptosis: from mechanism insights to targeted therapies
    Ziyi Xu, Ruochen Yang, Hudabia Akram +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Editorial: Targeted therapies in gastric cancer: molecular signatures and immune microenvironment insights
    Alessandro Mangogna, Laura Mariuzzi, Giuseppe Aprile +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  5. Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
    Arnau Domenech, Martí Hopmans, Erin Barker +2
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{ewart2026prostate,
  title = {{Prostate cancer: advancements in targeted therapies}},
  author = {Ilesha Ewart and Manreet Randhawa},
  journal = {Frontiers in endocrinology},
  year = {2026},
  month = oct,
  doi = {10.3389/fendo.2026.1924299},
  url = {https://europepmc.org/article/PMC/PMC13691727},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Prostate cancer: advancements in targeted therapies
AU  - Ilesha Ewart
AU  - Manreet Randhawa
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1924299
UR  - https://europepmc.org/article/PMC/PMC13691727
AB  - Prostate cancer is the most common cancer diagnosed in men. Metastatic castration-resistant prostate cancer (mCRPC) is associated with significant morbidity and mortality. The last decades have seen the introduction of multiple new therapeutic agents, such as androgen receptor pathway inhibitors, PARP inhibitors, new cytotoxic agents, and radioligand therapies. Further advancements are being made with immunotherapy utilising new molecular targets. As these treatments move earlier in the treatment pathway, determining the optimal treatment sequencing becomes the challenge. This review aimed to highlight established treatments, recent developments, and promising therapies in mCRPC.
SN  - 1664-2392
ER  -